Beneficial effect of CV-4151 (Isbogrel), a thromboxane A 2 synthase inhibitor, in a rat middle cerebral artery thrombosis model

By Imura Y.   Kiyota Y.   Nagai Y.   Terashita Z.-i.   Nishikawa K.  

Thrombosis Research, Vol. 79, Iss. 1, 1995-07 ,pp. : 95-107

Elsevier

Access to resources Recommend Favorite

Effect of DT-TX 30, a Combined Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, on Retinal Vascularity in Experimental Diabetes Mellitus - A novel device for assessing platelet behavior in blood

By De La Cruz J.P.   Moreno A.   Ruiz-Ruiz M.I.   De La Cuesta F.S.  

Thrombosis Research, Vol. 97, Iss. 3, 2000-02 ,pp. : 125-131

Elsevier

Access to resources Recommend Favorite

Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis

By Wang Xinkang   Smith Patricia   Hsu Mei-Yin   Tamasi Joseph   Bird Eileen   Schumacher William  

Journal of Thrombosis and Thrombolysis, Vol. 23, Iss. 1, 2007-02 ,pp. : 41-49

Springer Publishing Company

Access to resources Recommend Favorite

Synergistic Antithrombotic Effects of Argatroban and Ticlopidine In the Rat Venous Thrombosis Model - a small-molecule, direct thrombin inhibitor

By Morishita K.   Iwamoto M.  

Thrombosis Research, Vol. 92, Iss. 6, 1998-12 ,pp. : 261-266

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

By Wahlander K.   Lapidus L.   Olsson C.-G.   Thuresson A.   Eriksson U.G.   Larson G.   Eriksson H.  

Thrombosis Research, Vol. 107, Iss. 3, 2002-08 ,pp. : 93-99

Elsevier

Access to resources Recommend Favorite